For more, let's bring in Amy Burroughs, the CEO of Turns Pharmaceuticals. Amy, great to have you with us. >> Thank you so much for having me back, Melissa.>> This was stunning for most investors, most analysts out there in terms of of the data. Three times better approximately than the standard of care right now. Can you can you sort of speak to what this means for patients and and how soon this drug can actually reach market.>> Yeah, absolutely. So chronic myo leukemia is a disease which is a chronic condi ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Terns Pharmaceuticals, Inc. (NASDAQ:TERN) experienced a significant stock increase of 53% over the past week, driven by positive results from its therapy candidate for chronic myeloid leukemia (CML) [1][5]. Group 1: Clinical Results - The therapy candidate TERN-701 showed a 64% improvement in the conditions of 63 enrolled patients after 24 weeks of treatment [2]. - A major molecular response rate of 74% was observed at a higher dosage of 320 mg [2]. - Out of the total enrollees, 55 patients continued treatment, while four dropped out due to disease progression [2][3]. Group 2: Market Response - Following the positive clinical results, Terns Pharmaceuticals received a price target increase of 107% to $58 from Oppenheimer, which also assigned an "outperform" rating to the stock [3]. - Oppenheimer highlighted the potential of TERN-701 as a "best-in-class" therapy in the CML market [3]. Group 3: Financial Developments - Terns Pharmaceuticals successfully raised $747.5 million through the issuance of over 18.68 million shares at an offer price of $40 each, including the underwriters' full exercise of their overallotment option covering 2.4 million shares [4][5]. - The funds raised will be allocated for the development and commercial launch of TERN-701, as well as for working capital and other corporate purposes [5].

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the week, primarily buoyed by encouraging results from its therapy candidate for chronic myeloid leukemia (CML). In an updated report earlier in the week, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its therapy candidate TERN-701 recorded a 64 percent improvement in t ...

FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public offering of 18,687,500 shares of its common stock, including 2,437,500 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $40.00 per share, before underwriting discounts and commissions. The ...

Core Points - Terns Pharmaceuticals, Inc. announced the pricing of its upsized underwritten public offering of 16,250,000 shares at $40.00 per share, aiming for gross proceeds of $650 million [1] - The offering is expected to close on December 11, 2025, subject to customary closing conditions [1] - Terns has granted underwriters a 30-day option to purchase an additional 2,437,500 shares [1] Offering Details - Jefferies, TD Cowen, and Leerink Partners are the lead book-running managers for the offering, with Mizuho, Citizens Capital Markets, and Oppenheimer & Co. as co-managers [2] - A shelf registration statement was filed with the SEC on December 9, 2025, and became effective on the same date [4] Use of Proceeds - The net proceeds from the offering will be used to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, as well as for working capital and general corporate purposes [3][6]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the best performers on Monday. Terns soared to a new all-time high on Monday as investors took heart from the encouraging results of its clinical trial to test the efficacy of drug candidate, TERN-701, in patients with previously treated chronic myeloid leukemia (CML). At intra-day trading, the stock climbed to its highest price of $45 before trimming gains to finish the ...

Core Insights - Terns Pharmaceuticals presented updated data from the CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) patients, showing promising efficacy and safety results [1][3]. Efficacy Data - Among 38 efficacy-evaluable patients, the overall major molecular response (MMR) rate was 74% (28 out of 38) at 24 weeks, with 64% (18 out of 28) achieving MMR and 100% (10 out of 10) maintaining MMR [2][3]. - The deep molecular response (DMR) achievement rate was 29% by 24 weeks, with no patients losing MMR at the data cutoff [3][5]. - The reported MMR achievement rate of 64% is significantly higher than that of approved treatments like Scemblix and investigational agents, which reported rates of 24%-32% [8]. Safety Profile - The safety profile of TERN-701 was encouraging, with 87% (55 out of 63) of patients remaining on treatment as of the data cutoff [3]. - No dose-limiting toxicities were observed, and a maximum tolerated dose was not reached, indicating a favorable safety profile [3][4]. - The majority of treatment-emergent adverse events were low grade, with no apparent dose relationship [4]. Recommended Doses - The higher MMR achievement rate of 75% at doses of 320mg and above supports the selection of 320mg and 500mg QD as the recommended phase 2 doses for expansion [4][6]. Market Potential - Analysts believe TERN-701 has the potential to disrupt the CML treatment landscape, which has a global total addressable market (TAM) of approximately $5 billion [7]. - The consistency of efficacy data from the trial adds to the bullish sentiment among analysts regarding TERN-701's market prospects [9].